디프테리아, 파상풍 및 백일해(DTP) 백신 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of diphtheria, tetanus, and pertussis (DTP) vaccines Market

The global diphtheria, tetanus, and pertussis (DTP) vaccines market is experiencing robust expansion driven by rising infectious disease cases, strengthened immunization programs, and advancements in vaccine technologies. According to the report, the market reached USD 10.23 billion in 2024, is expected to grow to USD 11.69 billion by 2025, and is projected to surge to USD 33.38 billion by 2032, reflecting a strong trajectory as governments and global health organizations increase vaccination coverage. With DTP vaccines essential for preventing life-threatening bacterial infections, the market continues to gain momentum across pediatric and adult immunization programs.

Market Overview

DTP vaccines protect against three severe bacterial infections-diphtheria, tetanus, and pertussis-commonly affecting infants and young children. Multiple formulations such as DTaP, Tdap, DT/Td, and combination vaccines ensure broad applicability across age groups. Rising disease incidence is a critical factor driving adoption. The WHO reported over 62,500 global pertussis cases in 2022, with 39,000 in the Western Pacific region alone, highlighting the continued threat of whooping cough. These high infection rates reinforce the need for routine childhood immunization and booster programs.

Furthermore, leading pharmaceutical companies such as GSK plc, Sanofi, Merck & Co., Serum Institute of India, Biological E Limited, and BioNet-Asia strengthen the market with continuous supply, innovation, and global distribution capabilities.

Market Growth Drivers

High Burden of Vaccine-Preventable Diseases

Growing cases of respiratory bacterial infections are one of the most significant market drivers. CDC's Provisional 2024 Report revealed 35,435 pertussis cases in 2024, with over 6,500 cases in children aged 1-6 years. This has increased the urgency for active immunization, particularly among pediatric populations.

Expanding Vaccination Programs

Governments worldwide are initiating awareness campaigns to ensure timely vaccinations. For example, in April 2025, China launched a nationwide campaign during National Children's Vaccination Day to educate families on pertussis risks and the benefits of immunization.

Similarly, GAVI's 2023 update introduced DTP booster doses and hexavalent vaccines in eligible countries, enabling broader coverage.

Market Restraints

Vaccine Hesitancy & Lack of Awareness

In low-income regions, religious misconceptions, safety concerns, and limited education restrict vaccination uptake. In the Kyrgyz Republic, more than 22,000 children remained unvaccinated by end-2024 due to refusals and misinformation, demonstrating persistent challenges.

Cold Chain Limitations

Temperature-sensitive DTP vaccines require continuous storage between 2°C-8°C. According to India's National Vaccine Wastage Assessment, 13.5% of DPT vaccines were wasted due to cold-chain failures, directly affecting supply reliability.

Market Opportunities

Growing Government Support & Funding

Governments are investing heavily in nationwide vaccination drives. For instance, India's 2025 Td Vaccination Campaign for schoolchildren enhanced booster dose coverage. Similarly, Brazil and Guyana's Cross-Border Vaccination Week (2025) aims to immunize vulnerable populations.

Shift Toward Recombinant Technologies

Modern genetic engineering methods improve immunogenicity and duration of protection. BioNet-Asia's 2024 submission to EMA for its recombinant pertussis vaccine marks a shift toward safer, more effective vaccines, fueling new market growth avenues.

Segmentation Overview

By Technology

• Inactivated vaccines dominated 2024, driven by widespread use and WHO-reported 84% infant DTP-3 coverage in 2023.
• Recombinant technologies are expected to gain traction from 2025-2032 as companies develop safer, more immunogenic formulations.

By Type

• DTaP vaccines led 2024 due to their role in infant immunization.
• Tdap vaccines continue to expand moderately for older children, adults, and pregnant women.

By Age Group

• Pediatrics dominated the market in 2024 due to high infection rates and mandatory immunization schedules.
• Adults maintain steady demand through booster doses every 10 years.

By Distribution Channel

• Government suppliers held the largest share due to national immunization programs.
• Hospital and retail pharmacies are growing as access to vaccinations expands.

Regional Insights

North America

Generated USD 5.86 billion in 2024, leading globally due to high disease reporting, advanced health systems, and strong supply chains. U.S. pertussis cases surged to 11,568 in 2024, increasing vaccination demand.

Asia Pacific

Expected to grow at the highest CAGR through 2032, driven by cost-effective vaccines, large population, and government immunization drives.

Europe

Maintains strong share with WHO-recognized regulatory facilities, such as Germany's 2024 designation of a WHO Collaborating Center for Diphtheria.

Latin America & Middle East/Africa

Show moderate but rising adoption through cross-border and rural immunization initiatives.

Conclusion

With market value rising from USD 10.23 billion (2024) to USD 33.38 billion (2032), the global DTP vaccines market is poised for strong long-term expansion. Increasing disease prevalence, large-scale immunization campaigns, and advancements in recombinant technology will continue to strengthen global vaccine coverage and market growth.

Segmentation By Technology

• Inactivated
• Others

By Type

• DTaP Vaccine
• Tdap Vaccine
• DT/ Td vaccines
• Others

By Age Group

• Pediatric
• Adults

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Technology, Type, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries, 2024
• 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Overview: Vaccination Coverage for Diphtheria Tetanus and Pertussis (DTP) Vaccines, By Key Countries

5. Global Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Technology
  • 5.1.1. Inactivated
  • 5.1.2. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. DTaP Vaccine
  • 5.2.2. Tdap Vaccine
  • 5.2.3. DT/ Td vaccines
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adolts
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital & Retail Pharmacies
  • 5.4.2. Government Suppliers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Inactivated
  • 6.1.2. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. DTaP Vaccine
  • 6.2.2. Tdap Vaccine
  • 6.2.3. DT/ Td vaccines
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adolts
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital & Retail Pharmacies
  • 6.4.2. Government Suppliers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Inactivated
  • 7.1.2. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. DTaP Vaccine
  • 7.2.2. Tdap Vaccine
  • 7.2.3. DT/ Td vaccines
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adolts
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Government Suppliers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Inactivated
  • 8.1.2. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. DTaP Vaccine
  • 8.2.2. Tdap Vaccine
  • 8.2.3. DT/ Td vaccines
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adolts
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital & Retail Pharmacies
  • 8.4.2. Government Suppliers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Inactivated
  • 9.1.2. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. DTaP Vaccine
  • 9.2.2. Tdap Vaccine
  • 9.2.3. DT/ Td vaccines
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adolts
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital & Retail Pharmacies
  • 9.4.2. Government Suppliers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Diphtheria Tetanus and Pertussis (DTP) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Inactivated
  • 10.1.2. Others
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. DTaP Vaccine
  • 10.2.2. Tdap Vaccine
  • 10.2.3. DT/ Td vaccines
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adolts
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital & Retail Pharmacies
  • 10.4.2. Government Suppliers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sanofi
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Boryung Biopharma Co.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Serum Institute of India Pvt. Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Wuhan Institute of Biological Products Co., Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. BioNet-Asia.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bio Farma
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Biological E Limited.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)